Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection
1
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2
Department of Orthopedic Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
3
Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD 21201, USA
4
Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06520, USA
5
Yale Center for Phage Biology & Therapy, Yale University, New Haven, CT 06520, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Aneta Skaradzińska and Anna Nowaczek
Antibiotics 2022, 11(5), 616; https://doi.org/10.3390/antibiotics11050616
Received: 31 March 2022
/
Revised: 27 April 2022
/
Accepted: 2 May 2022
/
Published: 4 May 2022
(This article belongs to the Special Issue Bacteriophage Therapy: Recent Developments and Applications of a Renaissance Weapon)
Prosthetic joint infections are a devastating complication of joint replacement surgery. Consequently, novel therapeutics are needed to thwart the significant morbidity and enormous financial ramifications that are associated with conventional treatments. One such promising adjuvant therapeutic is bacteriophage therapy given its antibiofilm activity and its ability to self-replicate. Herein we discuss the case of a 70-year-old female who had a recalcitrant MRSA prosthetic knee and femoral lateral plate infection who was successfully treated with adjuvant bacteriophage therapy. Moreover, this case discusses the importance of propagating bacteriophage therapeutics on bacteria that are devoid of toxins and the need to ensure bacteriophage activity to all bacterial morphologies. Overall, this case reinforces the potential benefit of using personalized bacteriophage therapy for recalcitrant prosthetic joint infections, but more translational research is needed to thereby devise effective, reproducible clinical trials.
View Full-Text
Keywords:
bacteriophage therapy; Staphylococcus aureus; prosthetic joint infection; cell surface receptor; transaminitis
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Doub, J.B.; Ng, V.Y.; Lee, M.; Chi, A.; Lee, A.; Würstle, S.; Chan, B. Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics 2022, 11, 616. https://doi.org/10.3390/antibiotics11050616
AMA Style
Doub JB, Ng VY, Lee M, Chi A, Lee A, Würstle S, Chan B. Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics. 2022; 11(5):616. https://doi.org/10.3390/antibiotics11050616
Chicago/Turabian StyleDoub, James B., Vincent Y. Ng, Myounghee Lee, Andrew Chi, Alina Lee, Silvia Würstle, and Benjamin Chan. 2022. "Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection" Antibiotics 11, no. 5: 616. https://doi.org/10.3390/antibiotics11050616
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
